Background Increasing evidence suggests photoprotection by oral supplementation with b-carotene and lycopene. Objectives To examine the capacity of lycopene-rich tomato nutrient complex (TNC) and lutein, to protect against ultraviolet (UV)A/B and UVA1 radiation at a molecular level. Methods In a placebo-controlled, double-blinded, randomized, crossover study two active treatments containing either TNC or lutein were assessed for their capacity to decrease the expression of UVA1 the radiation-inducible genes HO1, ICAM1 and MMP1. Sixty-five healthy volunteers were allocated to four treatment groups and subjected to a 2-week washout phase, followed by two 12-week treatment phases separated by another 2 weeks of washout. Volunteers started either with active treatment and were then switched to placebo, or vice versa. At the beginning and at the end of each treatment phase skin was irradiated and 24 h later biopsies were taken from untreated, UVA/B-and UVA1-irradiated skin for subsequent reverse transcriptase polymerase chain reaction analysis of gene expression. Moreover, blood samples were taken after the washout and the treatment phases for assessment of carotenoids. Results TNC completely inhibited UVA1-and UVA/B-induced upregulation of heme-oxygenase 1, intercellular adhesion molecule 1 and matrix metallopeptidase 1 mRNA, no matter the sequence (ANOVA, P < 0Á05). In contrast, lutein provided complete protection if it was taken in the first period but showed significantly smaller effects in the second sequence compared with TNC. Conclusions Assuming the role of these genes as indicators of oxidative stress, photodermatoses and photoageing, these results might indicate that TNC and lutein could protect against solar radiation-induced health damage.
• Molecular markers for UVA1-inducible genes may be a suitable tool with which to address photodamage in human skin in vivo.
What is the translational message?
• Dietary strategies may help to protect human skin from UV radiation.
There is growing evidence that dietary intervention can protect human skin against the detrimental effects caused by solar ultraviolet (UV) radiation. 1 In this regard, carotenoids are of particular interest. 2 The vast majority of published studies have focused on b-carotene. Accordingly, based on the outcome of seven human intervention studies, [3] [4] [5] [6] [7] [8] [9] we previously performed a meta-analysis which showed that supplementation with bcarotene is associated with protection against the development of a sunburn reaction. 10 However, it should be noted that safety concerns were raised with regard to b-carotene supplements when they are taken over longer periods of time (i.e. years) at nonphysiological levels. Accordingly, in smokers and asbestos workers, a higher cumulative index for lung cancer has been observed. 11 As a consequence, more recent studies on oral photoprotection have included other carotenoids, as well as b-carotene. It was reported that a carotenoid mixture consisting of 8 mg each of b-carotene, lycopene and lutein provided a level of photoprotection similar to that achieved with 24 mg b-carotene. 5 Also, in an intervention study with lycopene-rich tomato paste, which provided 16 mg lycopene daily, a significant reduction of solar simulator-induced erythema was observed in human volunteers after 10 weeks of supplementation. 12 Of note, a combination of tomato phytonutrients from a tomato-based supplement resulted in better protection from UV-induced radiation than the effect of synthetic lycopene as a standalone treatment. 13 A randomized controlled trial showed that lycopene rich-tomato paste was able to prevent UV-induced effects at the molecular level. 14 The beneficial effect of the colourless tomato carotenoids phytoene and phytofluene in the protection of skin cells from UV damage was further supported in vitro. 15 All these in vivo studies used the UV-induced erythema response, which was induced by a solar simulator and consisted of a combination of UVB and UVA radiation as the readout system for photoprotection efficacy. This is somewhat surprising because (i) carotenoids are thought to provide photoprotection by acting as antioxidants (at least primarily); and because (ii) the solar simulator radiation-induced erythema response, which results from the UVB part of the emission spectrum, is mainly the consequence of the UVB radiation-induced formation of DNA photoproducts such as cyclobutane pyrimidine dimers, 16 that is, a photobiological event, which cannot be, or can only slightly be, reduced by antioxidants. However, it should be stated that shortwave UVB radiation and UVA radiation can cause oxidative stress. 17 Longwave UV radiation (UVA1)-induced gene expression might be a choice for readout, to show beneficial effects of antioxidants. Whether nutritional supplementation with lycopene and/or lutein can protect against UVA1 radiation-induced gene expression is not known. In the present placebo-controlled, double-blinded, randomized, crossover study, we assessed the capacity of two different nutritional supplements, that is, a lycopene-rich tomato nutrient complex (TNC) and a lutein containing one, to prevent not only UVB/A radiation (emitted from a solar simulator), but also UVA1 radiation-induced gene expression in human skin. Specifically, we analysed the mRNA expression of genes known to be UVA1-inducible, as well as UVB/A-inducible, and which are functionally involved in solar radiation-induced skin damage. These genes included HO1 as an indicator gene for oxidative stress (reviewed by Nisar et al.), 18 MMP1 (reviewed by Krutmann and Gilchrest), 19 which is critically involved in collagen breakdown and thus photoageing of human skin, and ICAM1, which plays an important role in skin inflammation and is expressed at increased levels in lesional skin of patients with polymorphic light eruption (PLE; reviewed in Vandergriff and Bergstresser).
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Materials and methods
Materials
TNC capsules and lutein-containing capsules, as well as placebo capsules, were provided by Lycored (Be'er Sheva, Israel). Lycopene-rich TNC softgel capsules contained 5 mg lycopene, as well as other tomato phytonutrients, such as phytoene and phytofluene, tocopherols and phytosterols. Lutein softgel capsules contained 10 mg free lutein stabilized by 10% carnosic acid, whereas placebo softgel capsules contained soybean oil. The latter proved to be an acceptable placebo in clinical trials addressing x3 fatty acid supplementation. 21 The UV blocking capacity of most natural oils was shown to be insufficient to obtain significant protection. 22 Specifically, while soybean oil is rich in x3 fatty acids, for example a-linolenic acid, its conversion into photoprotective long-chain x3 polyunsaturated fatty acids is poor in mammals. 23, 24 Correspondingly, no significant effect on UV responses could be detected for the biomarkers assessed under placebo treatment (see Figs 3 and 4 ). There was a slight colour difference between the placebo capsules and the capsules containing lycopene (which looked darker), but this difference was only recognizable during direct comparison. Dosage for the two different treatment arms was as follows: two capsules of TNC twice daily; one lutein capsule twice daily. All supplements were supplied in identically packed, coded containers.
Volunteers
The study was approved by the local ethics committee of the Heinrich-Heine University, D€ usseldorf, Germany (project no. 2869), and conducted at the IUF -Leibniz Research Institute for Environmental Medicine, D€ usseldorf, Germany, according to the ethical rules stated in the principles of the Declaration of Helsinki, and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines were adhered to, as applicable. Sixty-five healthy participants (52 men, 13 women) were enrolled, based on a power calculation with the following assumptions: based on a within-subject SD of the response variable (biomarker) of 30%, the probability was 80% that the study would detect a treatment difference at a two-sided 5% significance level, if the true difference between the treatments was > 20%. The study was conducted between November 2008 and October 2009. The age of the volunteers ranged from 18 to 60 years; all individuals were nonsmokers, had normal eating habits and no history of any skin disease or skin cancer. Further exclusion criteria were: pregnant or lactating women, intensely tanned skin and skin abnormalities in the test areas, sunbed use or sunbathing, and unusual eating habits (e.g. vegetarian). Participants were urged to keep a balanced diet without consuming tomatoes, tomato products and other dietary supplements.
Study design
The overall study design was that of a placebo-controlled, double-blinded, randomized crossover intervention study. For each nutritional supplement, two consecutive periods consisting of a washout phase of 2 weeks followed by a treatment phase of 12 weeks were carried out (Fig. 1) . The study consisted of two arms, a lycopene-rich TNC arm, and a lutein treatment arm. The participants enrolled at the IUF were distributed according to an online block randomization service by the sponsor; block size was four with an allocation ratio of 1: 1 per study arm: lycopene active group (TGA); lycopene placebo group (TGB); lutein active group (TGC); lutein placebo group (TGD). After the first treatment phase volunteers within one treatment arm were crossed over and the second washout phase and treatment phase were conducted. At the beginning of the study and at the end of each treatment phase participants were locally exposed to 1Á5 minimal erythemal dose (MED) of UVB/A using a solar simulator (Dr. K. H€ ohnle GmbH, Germany) with a lamp filter combination according to COLIPA standards, or UVA1 radiation (100 J cm À2 ) using a Sellamed 2000 device (Dr Sellmeier, Gevelsberg, Germany) with an emission spectrum of 340-400 nm as previously described. 25, 26 The individual MED was determined 24 h after irradiation of six skin areas on the upper buttock with increasing amounts of UVB/A as the lowest dose causing visible erythema. Blood samples drawn from the cubital vein were collected four times: at the end of the first washout phase, at the end of the first treatment phase, at the end of the second washout phase and at the end of the second treatment phase. Serum samples were prepared and stored at À80°C until high-performance liquid chromatography (HPLC) analysis for lycopene and lutein contents. Three 6-mm punch biopsies were obtained from buttock skin of each volunteer 24 h after irradiation. Irradiations were given at the end of the first washout phase, at the end of the first treatment phase and at the end of the second treatment phase. At each time point, one biopsy was taken from nonirradiated skin, one biopsy from UVB/A-irradiated skin and one biopsy from UVA1-irradiated skin.
Assessment of blood samples
Blood samples were collected in heparinized tubes and immediately centrifuged. Plasma was stored at À80°C until analysis. Carotenoids (lutein, zeaxanthin, b-cryptoxanthin, lycopene, a-and b-carotene) were analysed by HPLC with UV/visible detection as previously described.
27,28
Assessment of gene expression
Biopsies were snap frozen in liquid nitrogen and stored at À80°C until further analysis, which was done as previously described. 29, 30 For reverse transcriptase polymerase chain reac- (ÀDDC(T)) method was used. 35 Gene expression is indicated as x-fold induction vs. an unirradiated control.
Statistical analysis
Normality of the data was tested using the Shapiro-Wilk test. For comparison of significant differences, a paired test, t-test or ANOVA was used. In case of normality failure, the corresponding rank test, for example Wilcoxon signed rank test, Mann-Whitney rank sum test or Kruskal-Wallis ANOVA on ranks were employed. As post hoc analysis, the Tukey test was used as otherwise stated. A P-value < 0Á05 was considered significant. Data are presented as point or box plots with median and corresponding percentiles as indicated in the figure legends.
Results
For the lycopene-rich TNC arm of the study, 33 participants were recruited. 0Á221 nmol mL À1 (mean, t-test P = 0Á852)] prior to the intervention. Both carotenoids significantly increased upon intake of the lycopene-or lutein-containing capsules, but decreased to background levels or did not increase, respectively, when participants were treated with placebo. Lutein levels in the TGC group did not completely decrease to baseline after the second 2-week washout phase (Fig. 2b) . Nutritional intervention was well tolerated in all participants. With regard to safety, only one adverse event was reported by a volunteer from the lycopene arm of the study who suffered from diarrhoea a few days after starting with treatment. An external physician diagnosed the participant suffering from a viral infection of the upper intestine. The volunteer continued the study after a few days. , blood samples were taken, and ultraviolet (UV)A1 and UVA/B irradiations were performed. After 24 h, at day 16, three biopsies were taken. The first treatment phase began and lasted 12 weeks. At the end of the first treatment phase (day 100), blood samples were taken and UVA1 and UVA/B irradiations were performed. One day later (day 101), biopsies were taken and the second washout phase was started. At day 115, the second washout was finished, blood samples were taken and the second treatment phase started. After another 12 weeks (day 199), blood samples were taken and UVA1 and UVA/B irradiations were performed. One day later (day 200) biopsies were taken. Blood samples were used for determination of lycopene and lutein content. Biopsies were used for analysis of molecular markers.
Assessment of gene expression revealed that UVB/A, as well as UVA1, radiation significantly upregulated steady-state levels of HO-1, ICAM-1 and MMP-1 mRNA in skin of volunteers who were either untreated or had been treated with placebo. In marked contrast, TNC (Fig. 3) , as well as lutein (Fig. 4) , treatment significantly inhibited UVB/A and UVA1 radiationinduced gene expression.
As the factors for UVA1 and UVB/A induction of gene expression differed, we calculated, for further comparison, the remaining gene expression under active treatment as percentage of gene induction under nonprotected conditions, which had been set to 100%. The photoprotective effect of the active treatment did not differ between UVB/A-and UVA1-irradiated skin areas in both treatment arms (Table 1 ). In addition, we observed that the photoprotective effect of the active treatment did not differ in participants who were first treated with active agent and then crossed over to placebo, or who were first treated with placebo and then crossed over to active treatment in the lycopene-rich TNC arm of the study (Table 2 ). In contrast, we observed differences for the lutein arm (Table 2) . When lutein was given in the second phase of the treatment significantly lower photoprotection against UVA-induced ICAM-1 expression was detected, while the change for UVAinduced protection against HO-1 and MMP-1 was not significant (Table 2 ). For protection from UVB/A-induced gene expression, significantly lower protection was observed for all three markers studied ( Table 2) .
Lycopene-rich TNC and lutein supplementation did not significantly differ in their capacity to prevent UVB/A and UVA1 radiation-induced gene expression, when both active agents had been given in the first treatment phase (Table 2) . When lutein was given in the second treatment phase (TGD group) a decreased capacity to prevent UVA-induced upregulation of ICAM-1 or HO-1, and all UVA/B-induced markers assessed was determined (Table 3) .
Discussion
In this placebo-controlled, double-blinded, randomized, crossover study we assessed the capacity of a lycopene-rich TNC and a lutein-containing nutritional supplement to protect human skin against UV radiation (UVR). To the best of our knowledge we show here, for the first time, that (i) TNC and lutein do not only protect healthy human skin against UVB/A, but also against longwave UVA1 radiation; and (ii) that oral photoprotection of healthy human skin can be demonstrated at the level of HO1, ICAM1 and MMP1 gene expression.
This conclusion is based on the observation that intake of lycopene-rich TNC and lutein-containing capsules, in contrast to placebo capsules, was associated with a significant reduction of UVR-induced mRNA expression of HO-1, MMP-1 and ICAM-1 (Figs 3 and 4) .
These results corroborate and extend results from a previous study in which oral supplementation with a nutritional supplement containing TNC, b-carotene and Lactobacillus johnsonii was found to mitigate the development of skin lesions, as well as the concomitant upregulation of ICAM-1 mRNA in UVA1-irradiated lesional skin of patients with PLE. 29, 30 Taken together, these studies imply that oral photoprotection with selected carotenoids not only provides protection against shortwave UVB/A radiation, but also against longwave UVA1 radiation. The precise mechanism by which lycopene and lutein inhibit UVA1 radiation-induced gene expression is currently not known but most likely involves antioxidative mechanisms.
A strength of the study is the double-blind, randomized, controlled design. In addition, a sufficient number of volunteers was included based on a reasonable sample size. The crossover design increased the power and decreased the confounding covariates as each volunteer was his/her own control.
Frequently, a weakness of crossover studies is inappropriate washout phases. In the case of lycopene, a 2-week washout period seemed to be reasonable, as previously shown for serum levels. 36 Similarly, washout phases ≥ 2 weeks were sufficient to change serum lutein levels by supplementation from egg yolk. 37 A weakness of the crossover design was observed in the lutein arm, where we determined lower protection level if the lutein intake was preceded by 16 weeks of restricted diet due to washout and placebo treatment (Tables 2 and 3) . Obviously, the 12-week intake phase in the TGD group was not sufficient to reach similar blood levels as the patients in the TGC group (Fig. 2b) , as the lutein was accumulated somewhere else. 38 Accordingly, UVA1 radiation-induced gene expression was previously shown by us and others to involve, critically, the generation of singlet oxygen as an initiating event, [39] [40] [41] which most likely can be targeted by the wellknown capacity of carotenoids and of lycopene, in particular, to quench singlet oxygen. 2 These findings are of obvious clinical relevance because UVA1 radiation is well known to contribute to photoageing and photocarcinogenesis in healthy human skin, and to be an important trigger for the most frequent photodermatosis, that is, PLE. In this regard it is of interest that the genes we found to be reduced in their UVA1 inducibility are critically involved in these pathological conditions. Therefore, we suggest that oral supplementation with lycopene-rich TNC and lutein may be efficient in inhibiting UVA1 radiation-induced oxidative stress responses in general, and gene regulatory events involved in photoageing, photocarcinogenesis and photodermatoses specifically.
Notably, the TNC used in this study contained a combination of tomato phytonutrients. Previous studies suggest that the combined effect of tomato phytonutrients in protection from UV-induced erythema is stronger than the effect of lycopene as a standalone treatment. 13 Other tomato carotenoids, namely phytoene and phytofluene, have been suggested to have a protective effect of skin cells from UV damage. 15 The combination of lycopene with phytoene and phytofluene was recently suggested to be synergistic in another cellular model of prostate cells. 42 We suggest that the protective effect of the TNC in this study is the result of the combined effect of the tomato phytonutrients. To ingest 20 mg lutein and 20 mg lycopene, a cup of chopped kale (130 g) and a serving (242 g) of tomato juice would be enough. 43 Exposure to UVR is, to date, considered the primary preventable cause of skin ageing, a process that includes loss of elasticity, and drying and wrinkling. The specific genes found to be regulated in the current study might reflect on skin appearance. Accordingly, a significant correlation was found between forehead skin roughness and lycopene concentration in the skin of 40-50-year-old men and women. 44 Moreover, an antioxidant supplement containing TNC in combination with other phytonutrients was previously shown to support parameters related to skin structure and appearance, such as skin density, thickness, and roughness and scaling. 45 It should also be noted that inhibition of UVA1-and also of UVA/B-induced gene expression by lycopene-rich TNC and lutein supplementation was shown in relatively small groups of only 30 study participants. This observation emphasizes that a combination of a crossover design together with the assessment of gene expression as a highly sensitive biological end point represents a study design well suited to examine the efficacy of nutritional strategies for skin health, including photoprotection.
Further clinical trials addressing in vivo effects, such as an increase in the MED, are necessary to verify the impact of the molecular findings on human skin. 
